Unexpected long-term survival after low-dose palliative radiotherapy for nonsmall cell lung cancer

Cancer

Volumn 106, Issue 5, 2006, Pages 1110-1116

  Mac Manus, Michael P ^a   Matthews, Jane P ^a   Wada, Morikatsu ^b   Wirth, Andrew ^a   Worotniuk, Valentina ^a   Ball, David L ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Cure; Nonsmall cell lung cancer; Radiation therapy; Survival analysis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; FEMALE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33644530039     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21704     Document Type: Article

References (28)

1. Penland SK, Socinski MA. Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin Radiat Oncol. 2004;14:326-334.
2. Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer. 1997;21:129-183.
3. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin Oncol. 1999;17:3188-3194.
4. Shepherd FA. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol. 1999;26(1 Suppl 4):3-11.
5. Macbeth FR, Bolger JJ, Hopwood P, et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol). 1996;8:167-175.
6. Simpson JR, Francis ME, Perez-Tamayo R, Marks RD, Rao DV. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multiinstitutional trial. Int J Radiat Oncol Biol Phys. 1985;11:751-758.
7. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer. 1998;34:1036-1044.
8. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995;13:1221-1230.
9. Ball D, Matthews J, Worotnouk V, Crennan E. Longer survival with higher doses of thoracic radiotherapy in patients with limited non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993;25:599-604.
10. Fowler JR. Brief summary of radiobiological principles in fractionated radiotherapy. Semin Radiat Oncol 1992;2:16-21.
11. Mac Manus MP, Wada M, Matthews J, Ball DL. Characteristics of 47 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure. Int J Radiat Oncol Biol Phys. 2000;46:63-69.
12. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1711-1717.
13. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343-346.
14. Kaplan ES, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-480.
15. Quddus AM, Kerr GR, Price A, Gregor A. Long-term survival in patients with non-small cell lung cancer treated with palliative radiotherapy. Clin Oncol. 2001;13:95-98.
16. Satoh H, Ishikawa H, Naito T, et al. Analysis of long-term survivors after platinum containing chemotherapy in non-small cell lung cancer. Anticancer Res. 1998;18:1295-1298.
17. Sculier JP, Paesmans M, Libert P, et al. Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working party. Eur J Cancer. 1994;30A:1342-1347.
18. Saitoh Y, Fujisawa T, Shiba M, et al. Prognostic factors in surgical treatment of solitary brain metastasis after resection of non-small-cell lung cancer. Lung Cancer. 1999;24:99-106.
19. Leo F, Nicholson AG, Hansell DM, Corrin B, Pastorino U. Spontaneous regression of large-cell carcinoma of the lung: a rare observation in clinical practice. Thorac Cardiovasc Surg. 1999;47:53-55.
20. Kappauf H, Gallmeier WM, Wunsch PH, et al. Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer. Case report, review of the literature, and discussion of possible biological pathways involved. Ann Oncol. 1997;8:1031-1039. Review.
21. Schofield P, Ball D, Smith JG, et al. Optimism and survival in lung carcinoma patients. Cancer. 2004;100:1276-1282.
22. Peters LJ. The ESTRO Regaud lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother Oncol. 1990;17:177-190.
23. Shahidi H, Kvale PA. Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest. 1996;109:271-276.
24. Luketich JD, Burt ME. Does resection of adrenal metastases from non-small cell lung cancer improve survival? Ann Thorac Surg. 1996;62:1614-1616.
25. Porte HL, Roumilhac D, Graziana JP. Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg. 1998;65:331-335.
26. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Cancer. 1980;45:2744-2753.
27. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
28. Saunders MI, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. Lancet. 1997;350:161-165.